BGT226 maleate (also known as NVP-BGT226 maleate) is a novel and potent dual inhibitor of class I PI3K (phosphatidylinositol 3-kinase)/mammalian target of rapamycin (mTOR) with potential anticancer activity.

ETP-46321 is a novel, potent and orally bioavailable inhibitor of PI3Kα and PI3Kδ with Kiapp values of 2.3 nM and 14.2 nM, respectively in biochemical assays.

VPS34-IN1 (VPS34-IN-1) is a novel and potent Vps34 (vacuolar protein sorting 34) inhibitor with potential antitumor activity.

AZD8186 (also known as AZD) is a novel, potent and selective inhibitor of PI3Kβ (phosphatidylinositol 3-kinase β) with potential anticancer activity.

Inavolisib (RG6114; GDC0077), extracted from patent WO 2017001645 A1, formula I, is a novel, potent and orally bioavailable PI3K inhibitor with potential anticancer activity.

HS-173 is a novel and potent PI3Kα (phosphatidylinositol 3-kinase) inhibitor (IC50 = 0.8 nM) with a potential to be used as an effective therapeutic agent for ameliorating liver fibrosis.

IPI-3063 is a potent and selective PI3K p110δ inhibitor with IC50 of 2.5 ± 1.2 nM and IC50 values of >1000 nM for other classes of PI3K isoforms (p110α, p110β, p110γ).

GSK2292767 is a novel and selective PI3Kδ inhibitor being investigator for the treatment of respiratory diseases such as asthma and COPD.

PF-4989216 is a novel, potent, orally bioactive and selective small molecule inhibitor of PI3K (phosphatidylinositol 3-kinase) with potential anticancer activity.

740 Y-P is a cell-permeable peptide acting as a phosphopeptide activator of PI3K. 740 Y-P plays an important role in PI3K/AKT signaling pathway.